NCT07343037 Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care
| NCT ID | NCT07343037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Strasbourg, France |
| Condition | Hepatic Insufficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-08-29 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-08-29 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings. In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction. The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.
Eligibility Criteria
Inclusion Criteria: * Adult patient (≥18 years old) * Patient admitted to the intensive care unit at Hautepierre Hospital, Strasbourg University Hospital, between January 1, 2014, and December 31, 2024 * At least 3 biological signs of HLH: * ferritin \> 2000 ng/mL * triglycerides \> 1.5 g/L * at least one cytopenia (leukocytes ≤ 5000 G/L, platelets ≤ 110 G/L, hemoglobin ≤ 9.2 g/dL). Exclusion Criteria: Refusal to participate in the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07343037 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatic Insufficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07343037 currently recruiting?
Yes, NCT07343037 is actively recruiting participants. Contact the research team at antonin.hugerot@chru-strasbourg.fr for enrollment information.
Where is the NCT07343037 trial being conducted?
This trial is being conducted at Strasbourg, France.
Who is sponsoring the NCT07343037 clinical trial?
NCT07343037 is sponsored by University Hospital, Strasbourg, France. The trial plans to enroll 100 participants.